Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterol Hepatol. 2022 Nov;45(9):724-734.
doi: 10.1016/j.gastrohep.2022.02.005.
Epub 2022 Mar 3.
[Article in
English,
Spanish]
Authors
Rocío Gallego-Durán
1
, Agustín Albillos
2
, Javier Ampuero
3
, María Arechederra
4
, Rafael Bañares
5
, Ana Blas-García
6
, Genoveva Berná
7
, Esther Caparrós
8
, Teresa C Delgado
9
, Juan Manuel Falcón-Pérez
10
, Rubén Francés
8
, Maite G Fernández-Barrena
4
, Isabel Graupera
11
, Paula Iruzubieta
12
, Yulia A Nevzorova
13
, Rubén Nogueiras
14
, Rocío I R Macías
15
, Franz Martín
7
, Guadalupe Sabio
16
, Germán Soriano
17
, Javier Vaquero
18
, Francisco Javier Cubero
19
, Jordi Gracia-Sancho
20
Affiliations
- 1 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; SeLiver Group, Instituto de Biomedicina de Sevilla/Consejo Superior de Investigaciones Científicas (CSIC)/Universidad de Sevilla, Sevilla, Spain.
- 2 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Gastroenterology and Hepatology Department, Ramón y Cajal Hospital/Alcalá University/IIS Ramón y Cajal (IRYCIS), Madrid, Spain.
- 3 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; SeLiver Group, Instituto de Biomedicina de Sevilla/Consejo Superior de Investigaciones Científicas (CSIC)/Universidad de Sevilla, Sevilla, Spain; UCM Digestive Diseases, Virgen del Rocío University Hospital, Sevilla, Spain.
- 4 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Program of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
- 5 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Gregorio Marañón Hospital, Madrid, Spain; IIS Gregorio Marañón (IiSGM), Madrid, Spain; Department of Medicine, Complutense University School of Medicine, Madrid, Spain.
- 6 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; FISABIO - University Hospital Dr Peset, Valencia, Spain; Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain.
- 7 Biomedical Research Network on Diabetes and Related Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain; Andalusian Center of Molecular Biology and Regenerative Medicine-CABIMER, Seville, Spain; University Pablo Olavide-University of Seville-CSIC, Seville, Spain.
- 8 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Clinical Medicine Department, Miguel Hernández University, San Juan De Alicante, Spain; IIS Isabial, Alicante General Hospital, Alicante, Spain.
- 9 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
- 10 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Exosomes Laboratory & Metabolomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain; Basque Foundation for Sciences, Ikerbasque, Bilbao, Spain.
- 11 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Liver Unit, Hospital Clínic de Barcelona, IDIBAPS Biomedical Research Institute, Barcelona, Spain.
- 12 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Aparato Digestivo, Marqués de Valdecilla Hospital, Santander, Spain.
- 13 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; IIS Gregorio Marañón (IiSGM), Madrid, Spain; Department of Immunology, Opthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Department of Internal Medicine III, University Hospital RWTH, Aachen, Germany.
- 14 Biomedical Research Network on Obesity and Nutrition (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain; Department of Physiology, CIMUS, University of Santiago de Compostela, Spain; IIS Santiago de Compostela, Spain.
- 15 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, Salamanca, Spain.
- 16 Myocardial Pathophysiology, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- 17 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- 18 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; IIS Gregorio Marañón (IiSGM), Madrid, Spain.
- 19 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; IIS Gregorio Marañón (IiSGM), Madrid, Spain; Department of Immunology, Opthalmology and ENT, Complutense University School of Medicine, Madrid, Spain.
- 20 Biomedical Research Network on Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain; Liver Vascular Biology, IDIBAPS Biomedical Research Institute, Barcelona, Spain; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: jordi.gracia@idibaps.org.
Abstract
This is a meeting report of the 3rd Translational Hepatology Meeting held in Alicante, Spain, in October 2021. The meeting, which was organized by the Spanish Association for the Study of the Liver (AEEH), provided an update on the recent advances in the field of basic and translational hepatology, with a particular focus on the molecular and cellular mechanisms and therapeutic targets involved in metabolic-associated fatty liver disease (MAFLD), metabolic-associated steatohepatitis (MASH), cirrhosis and end-stage hepatocellular carcinoma (HCC).
Keywords:
Carcinoma hepatocelular; Esteatohepatitis; Esteatosis; Fibrosis; Hepatocellular carcinoma; MAFLD; MASH; Steatohepatitis.
Copyright © 2022 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Carcinoma, Hepatocellular* / complications
-
Carcinoma, Hepatocellular* / therapy
-
Gastroenterology*
-
Humans
-
Liver Cirrhosis / complications
-
Liver Cirrhosis / pathology
-
Liver Neoplasms* / complications
-
Liver Neoplasms* / therapy
-
Non-alcoholic Fatty Liver Disease* / complications
-
Non-alcoholic Fatty Liver Disease* / pathology
-
Non-alcoholic Fatty Liver Disease* / therapy